LA+Pharma SRL
0.9 FTEThe score of LA+Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +154 % Total assets +29 % Headcount (avg FTE) -10 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
LA+Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 127,041 € | ||||
| Equity | 614,605 € | ||||
| Cash | 400,508 € | ||||
| EBITDA | 283,864 € | ||||
| Total assets | €1.44m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 28 Aug 2025
- Year ended 31 Dec 2023filed on 13 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
LA+Pharma's financial analysis
- Solvency42.6%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of LA+Pharma
LA+Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0845.973.424
- VAT number
- BE0845973424
- Peppol
- Registered · 0208:0845973424 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 15 May 2012
- Registered office
- 8650 Houthulst
- Size
- Micro · 0.9 FTE
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
LA+Pharma (SRL) has been based in Houthulst since 2012, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 127,041 € and equity of 614,605 €; its revenue is not published. With 0.9 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 42.6%, below the median of its sector (44.2%).
Companies similar to LA+Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Marie Renaux Retail sale of pharmaceutical products Charleroi · balance sheet €1.44m
- De Latemse Apotheek Retail sale of pharmaceutical products Sint-Martens-Latem · balance sheet €1.44m
- Apotheek Mortelmans Retail sale of pharmaceutical products Heist-op-den-Berg · balance sheet €1.44m
- C.E. Farma Retail sale of pharmaceutical products Oostrozebeke · balance sheet €1.45m
- Natessence Retail sale of pharmaceutical products Écaussinnes · balance sheet €1.43m
- Alpha pharma Retail sale of pharmaceutical products Roeselare · balance sheet €1.45m
- Laleman Pharma Retail sale of pharmaceutical products Diksmuide · balance sheet €1.43m
- Duopharm Retail sale of pharmaceutical products Lebbeke · balance sheet €1.43m
Frequently asked questions about LA+Pharma
What is the revenue of LA+Pharma?
LA+Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of LA+Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0845973424 for LA+Pharma, if the company is VAT-registered. Its company number (CBE) is 0845.973.424.
Where is the registered office of LA+Pharma?
According to the CBE register, the registered office of LA+Pharma is in 8650 Houthulst.
What is the equity of LA+Pharma?
At the close of the 2025 financial year, the equity of LA+Pharma amounts to 614,605 €, a solvency of 42.6% of total assets.
How many people work at LA+Pharma?
0.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages LA+Pharma?
The register lists 1 active mandates at LA+Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of LA+Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →